1. Home
  2. LEXX vs PRPH Comparison

LEXX vs PRPH Comparison

Compare LEXX & PRPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • LEXX
  • PRPH
  • Stock Information
  • Founded
  • LEXX 2004
  • PRPH 1989
  • Country
  • LEXX Canada
  • PRPH United States
  • Employees
  • LEXX N/A
  • PRPH N/A
  • Industry
  • LEXX Biotechnology: Pharmaceutical Preparations
  • PRPH Biotechnology: Pharmaceutical Preparations
  • Sector
  • LEXX Health Care
  • PRPH Health Care
  • Exchange
  • LEXX Nasdaq
  • PRPH Nasdaq
  • Market Cap
  • LEXX 22.7M
  • PRPH 21.9M
  • IPO Year
  • LEXX N/A
  • PRPH 1997
  • Fundamental
  • Price
  • LEXX $1.06
  • PRPH $0.29
  • Analyst Decision
  • LEXX Strong Buy
  • PRPH
  • Analyst Count
  • LEXX 1
  • PRPH 0
  • Target Price
  • LEXX $4.00
  • PRPH N/A
  • AVG Volume (30 Days)
  • LEXX 283.7K
  • PRPH 1.3M
  • Earning Date
  • LEXX 11-25-2025
  • PRPH 11-07-2025
  • Dividend Yield
  • LEXX N/A
  • PRPH N/A
  • EPS Growth
  • LEXX N/A
  • PRPH N/A
  • EPS
  • LEXX N/A
  • PRPH N/A
  • Revenue
  • LEXX $615,923.00
  • PRPH $5,588,000.00
  • Revenue This Year
  • LEXX $46.98
  • PRPH $221.82
  • Revenue Next Year
  • LEXX $17.26
  • PRPH N/A
  • P/E Ratio
  • LEXX N/A
  • PRPH N/A
  • Revenue Growth
  • LEXX 49.85
  • PRPH N/A
  • 52 Week Low
  • LEXX $0.77
  • PRPH $0.22
  • 52 Week High
  • LEXX $2.85
  • PRPH $2.17
  • Technical
  • Relative Strength Index (RSI)
  • LEXX 56.87
  • PRPH 31.53
  • Support Level
  • LEXX $0.99
  • PRPH $0.29
  • Resistance Level
  • LEXX $1.21
  • PRPH $0.39
  • Average True Range (ATR)
  • LEXX 0.08
  • PRPH 0.04
  • MACD
  • LEXX 0.02
  • PRPH -0.02
  • Stochastic Oscillator
  • LEXX 58.97
  • PRPH 4.02

About LEXX Lexaria Bioscience Corp.

Lexaria Bioscience Corp's patented drug delivery technology, DehydraTECH improves the way active pharmaceutical ingredients enter the bloodstream by promoting more effective oral delivery. DehydraTECH can increase bio-absorption with cannabinoids and nicotine by 5-10x and, in some instances with cannabinoids by as much as 27x compared to standard industry formulations, reduce the time of onset from 1-2 hours to minutes, and mask unwanted tastes. DehydraTECH has also evidenced an ability to deliver some drugs more effectively across the blood-brain barrier. The company has four reportable segments: Intellectual Property Licensing which generates maximum revenue, B2B Production, Research and Development, and Corporate. Geographically, it derives revenue from the United States and Canada.

About PRPH ProPhase Labs Inc. (DE)

ProPhase Labs Inc is a diversified company offering various services, including diagnostic testing, genomics testing, and contract manufacturing. Its operating segments include Diagnostic services and Consumer products. The Diagnostic segment provides COVID-19 diagnostic information services to a broad range of customers in the United States, including health plans, third-party payers, and government organizations. The Consumer Products segment is engaged in the research, development, manufacture, distribution, marketing, and sale of OTC consumer healthcare products and dietary supplements in the United States. It also provides personal genomics products and services.

Share on Social Networks: